Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NVUS

Novus Therapeutics (NVUS) Stock Price, News & Analysis

Novus Therapeutics logo

About Novus Therapeutics Stock (NASDAQ:NVUS)

Advanced Chart

Key Stats

Today's Range
$3.36
$3.51
50-Day Range
$9.85
$16.50
52-Week Range
$4.50
$27.32
Volume
325,275 shs
Average Volume
78,851 shs
Market Capitalization
$4.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NVUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NVUS Stock News Headlines

Ptc Therapeutics Share Price (PTCT.US)
CAMP4 Therapeutics Corp.
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Tango Therapeutics Share Price (TNGX.US)
Sarepta Therapeutics Share Price (SRPT.US)
Vivoryon Therapeutics NV VVY
Viking Therapeutics Inc
CYT Cyteir Therapeutics, Inc.
See More Headlines

NVUS Stock Analysis - Frequently Asked Questions

Novus Therapeutics, Inc. (NASDAQ:NVUS) posted its earnings results on Monday, November, 16th. The biopharmaceutical company reported ($5.51) EPS for the quarter, missing the consensus estimate of ($1.64) by $3.87.

Shares of Novus Therapeutics reverse split on Monday, October 5th 2020.The 1-18 reverse split was announced on Friday, October 2nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Novus Therapeutics investors own include SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Sorrento Therapeutics (SRNE), Bristol Myers Squibb (BMY), Miragen Therapeutics (MGEN), Selecta Biosciences (SELB) and Tonix Pharmaceuticals (TNXP).

Company Calendar

Last Earnings
11/16/2020
Today
7/12/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NVUS
CIK
1404281
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($21.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$16.01 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-133.49%
Return on Assets
-30.52%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
18.78
Quick Ratio
18.78

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$13.13 per share
Price / Book
0.26

Miscellaneous

Outstanding Shares
1,436,000
Free Float
N/A
Market Cap
$4.91 million
Optionable
Not Optionable
Beta
2.07
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:NVUS) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners